The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
Problem is the lack of company updates and drumming up their funding crisis way too often in last few presentation they had. Remember what Richard wrote on his FDA RNS back in Dec 2022? "The commercial team at Polarean is prepared to rapidly launch XENOVIEW for clinical application." he said. Turned out they needed reimbursement codes, permission in each and every state separately and their coils need to be approved too by FDA but still no sales so looking for the gas exchange market to justify any further investment case. We all loved the tech, it's story, it's potential but the reality turned out to be something different which is a big shame. Patience are now running wafer thin and their silence is not helping either apart from CEO's occasional motivational speech on LinkedIn, including him being an acrobat!
Any commercial deals with other majors would be a big welcome news for sure? That Cyclopharms is a wakeup call for the management that time is running out quickly. We are almost a year down on our Hatch waxman protection too.
Jam2morrow
Xenoview is just too expensive making it a bit Luxury to be honest. £500k for a machine, then $1200 per scan whereas cyclopharms is around $149 or something. Polarean needs sell to prove the machine is worth it. They surely needs more time and funds as they burned further £2.47M since June and we are approaching mid Oct so further £412k almost gone now. On theory it’s a good tech but we are yet to see some prof otherwise every rise will be sold. Meeting FDA for gas exchange this month apparently so let’s see what they come up with. Another FDA submission will delay the who thing further 6 months as far as I know.
It's taking time but one day #fab will have a super rise.
Https://www.wired.com/story/labgenius-antibody-factory-machine-learning/
AI Is Building Highly Effective Antibodies That Humans Can’t Even Imagine
Robots, computers, and algorithms are hunting for potential new therapies in ways humans can’t—by processing huge volumes of data and building previously unimagined molecules.
Patience formerly, the toughest time is behind the company now. Company is now getting back to growth again. Give it some times, it will bounce back strongly with new contract news.
https://twitter.com/FsnAntibodies/status/1709921672474534239
Https://www.insideprecisionmedicine.com/topics/translational-research/twist-bioscience-bayer-enter-antibody-discovery-deal-valued-at-up-to-188-million/
"Twist Bioscience, Bayer Enter Antibody Discovery Deal Valued at up to $188 Million
October 5, 2023"
It's a very very uncomfortable situation for me like most on this BB. I thought the same thing with gfin and twd. The conviction was super high but it turned out the gfin ceo was simply lying about their accomplishments while their results were saying something else, was pumping Athlos being the next big thing, spent millions on it only to sell it for a £1 while twd was always an inch away from a new deal which never came. Now somebody will probably buy it from administration for a £1. Two things keeping me awake at night is that the CEO never bought any shares after the interim when he could just to boost some investors confidence, sentiments and align his interest with us long suffering shareholders. CFO always looks like a mental case anyway. When asked what the company did after CRL, he said we actively communicated with FDA when we wanted to know if they have done anything to facilitate their commercialisation during that period. In other words they just took their overly generous wages and bonuses at our expense while playing golf and attending shows. I noticed the CEO posted he is an acrobat while us going down on a daily basis. if the 150k seller comes back again, it won't take much for the SP to drop in 5-6p region next week. :(
I'm probably getting extremely frustrated now. I had high hope on polx, did reduce my holdings but still kept a chunky amount in but given the SP is falling on a daily basis, thanks to our 150K seller(s), even I'm losing my patience now. :(
This bit started me thinking what if Polarean is not giving us the real picture and allowing people in the know to sell their stocks constantly while we argue, speculate and count our losses on a daily basis! :(
“Three-dimensional imaging doesn’t work with Xenon, because it's a low energy isotope. And then technetium DTPA is a wet aerosol that starts to pool as soon as it comes out of the nebulizer, and if there's any narrowing of the lungs, it masks a lot of the functional aspects of the lung … so that’s why the U.S. was stuck back in the 1990s.”
“We even had doctors writing to the FDA, and the Society of Nuclear Medicine and Molecular Imaging wrote to the FDA to try to lobby [the agency] to push our approval through,” he said, noting that Cyclopharm received 420 expressions of interest for the product, so it’s not a matter of “getting a sales force together, it’s about the execution in getting the generators to the U.S. and installing them.”
The phase III trial supporting the NDA was a noninferiority structural ventilation study comparing Technegas with Xenon-133 in 240 patients. The trial met both primary and secondary safety and efficacy endpoints.
Technegas is most commonly used in the diagnosis and management of PE. Over the past three decades it has been successfully used in 64 countries worldwide, amassing 4.7 million patient studies. In each of these countries, the technology has become accepted as the preferred nuclear medicine lung ventilation imaging agent.
“By every measure, we're better than the competing products, and that's why we are named in clinical guidelines in Canada, which is our largest country market, and in Europe, which is our largest region.”
Promoting? That is the last thing in my mind right now. I was highlighting their FDA approval and their strategy to commercialise their products. I was wondering is this why polx failed to sold any xenoview todate or atleast get some indication that people might buy some in the future because hospitals had other plans?
So far it's the CEO claiming clinicians want but their results todate shows a different story. They kept highlighting about their funding issues and now BigSlick 7 highlighting Amati might be loaning stocks to short answer why the SP is falling like a stone.
I've asked Anna from walbrook but received an auto reply instead stating she is out till 10th oct. Just wanted to find out if this tech poses an existential threat for Xenoview. Company never replies directly anyway. Extremely disappointing and frustrating.
Didn't understand a line she was saying. I thought it was an Australian company.
https://www.cyclopharm.com/
Lots of big sells are going through. It seems the market is convinced polx is destined to fail, I hope not but the next raise would be extremely painful for the remaining shareholders. It is company's duty to protect it's shareholders and deliver. It seems they have forgotten it and enjoying their more than generous wages and ready to get their begging bowl out soon. Shame: (
"Hopefully a lot of the hospitals chose the safest option for patients and staff, with a great ROI, then we should be okay"
I used to as optimistic as you are mate but millions of hospitals are still using xray and other radio active scans so it seems cost would be the main factor to decide. Since this management has failed to generate any interest in new sale, it seems this tech is either destined to fail or somebody to buy them for peanuts out of administration. Eitherway it's another disaster for loyal shareholders like us. That 150K daily seller is not going to stop so it will keep going down and down.
The CEO still doesn't hold any shares so it's not his headache to do anything to boostup the sentiment or SP. Not sure if the CFO holds any either. Really sad times ahead.
"The commercial rollout will begin immediately, McBrayer said, noting that the company will now complete final assembly of its first wave of 200 generators, with plans for the first air shipments to arrive in the U.S. by early November. Cyclopharm will leverage the company’s sales and operational expertise across 64 countries globally in which the product is already approved and established.
U.S. reimbursement codes are based on established nuclear medicine procedures, which means Technegas can be immediately reimbursed under existing bundled procedural codes for $140 per patient."